Table 4.

Characteristics of BC patients who died at follow-up and who survived.

Variable	Died n = 55 (%)	Survived n = 453 (%)	p
Age (mean ± SD)	68 ± 11	63 ± 13	0.01
Age >65 years	36 (66)	223 (49)	0.03
Cancer setting			<0.001
Neoadjuvant	9 (16)	99 (22)
Adjuvant	11 (20)	284 (63)
Advanced	35 (64)	70 (16)
Previous exposure to anthracyclines	13 (24)	26 (6)	<0.001
Anticancer treatments
Anthracyclines	16 (29)	271 (60)	<0.001
Cumulative dose (mean ± SD; mg/mq; not liposomal)	344 ± 89	353 ± 67	0.59
Anti-HER2	10 (18)	155 (34)	0.02
Only trastuzumab	4 (7)	125 (28)	<0.001
Trastuzumab and pertuzumab	6 (11)	30 (7)	0.26
Anthracyclines+anti-HER2	3 (6)	88 (19)	0.01
Number of Cardio-Oncology evaluations (median, [range])	2 [1–15]	2 [1–10]	0.74
Arterial hypertension	32 (58)	200 (44)	0.06
Dyslipidaemia	33 (60)	269 (59)	1
Diabetes mellitus	9 (16)	38 (8)	0.08
Tobacco smoking	20 (36)	165 (36)	1
Active	9 (16)	67 (15)	0.69
Family history of CAD	5 (9)	58 (13)	0.52
≥2 CV risk factors	32 (59)	235 (52)	0.40
BMI > 30 kg/mq	7 (13)	62 (14)	1
Chronic kidney disease	2 (4)	14 (3)	0.69
Known CV conditions
CAD	2 (4)	11 (2)	0.64
PAD	5 (9)	23 (5)	0.21
AF	7 (13)	16 (4)	0.01
HF	2 (4)	8 (2)	0.30
LVH	16 (29)	95 (21)	0.17
Moderate-to-severe VHD	3 (6)	17 (4)	0.47
Mean LVEF	59 ± 3	60 ± 3	0.24
LVD	0 (0)	15 (3)	0.39
Other CV events	4 (7)	6 (1)	0.02

BC, breast cancer; HER2, human epidermal growth factor receptor 2; CV, cardiovascular; CAD, coronary artery disease; PAD, peripheral artery disease; AF, atrial fibrillation; HF, heart failure; LVH, left ventricular hypertrophy; VHD, valvular heart disease; LVEF, left ventricular ejection fraction; LVD, left ventricular dysfunction. The bold values highlight significant p values.